Back to Journals » Drug Design, Development and Therapy » Volume 5
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates
Authors Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L
Published 19 October 2011 Volume 2011:5 Pages 445—454
DOI https://doi.org/10.2147/DDDT.S12139
Review by Single anonymous peer review
Peer reviewer comments 4
Maurizio Muratore, Eugenio Quarta, Antonella Grimaldi, Fabio Calcagnile, Laura Quarta
Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy
Abstract: Bisphosphonates have a long history in the treatment of osteoporosis and bone-related disease. This review focuses on the use of a specific nonaminobisphosphonate, clodronate, which appears to be much better tolerated than other bisphosphonates and free of high-risk contraindications. Specifically, this paper reviews its use in the prevention of osteoporosis in postmenopausal women, taking into account its tolerability profile and recent safety issues arising regarding the use of bisphosphonates.
Keywords: clodronate, bisphosphonates, osteoporosis, bone turnover, menopause, tolerability
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.